101 related articles for article (PubMed ID: 26780780)
1. Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer.
Jatoi A; Vierkant RA; Hawthorne KM; Block MS; Ramus SJ; Larson NB; Fridley BL; Goode EL
Oncology; 2016; 90(2):59-68. PubMed ID: 26780780
[TBL] [Abstract][Full Text] [Related]
2. What Is the Clinical Value Associated with Defining Additional Disease-Specific 'Prognostic Indicators'?
Markman M
Oncology; 2016; 90(2):57-8. PubMed ID: 26837006
[No Abstract] [Full Text] [Related]
3. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
4. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
7. Nestin: A biomarker of aggressive uterine cancers.
Hope ER; Mhawech-Fauceglia P; Pejovic T; Zahn CM; Wang G; Conrads TP; Larry Maxwell G; Hamilton CA; Darcy KM; Syed V
Gynecol Oncol; 2016 Mar; 140(3):503-11. PubMed ID: 26718725
[TBL] [Abstract][Full Text] [Related]
8. FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression.
Lloreta J; Font-Tello A; Juanpere N; Frances A; Lorenzo M; Nonell L; de Muga S; Vázquez I; Cecchini L; Hernández-Llodrà S
Hum Pathol; 2017 Apr; 62():222-231. PubMed ID: 28087474
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
10. A multifactorial prognostic model for adult soft tissue sarcoma considering clinical, histopathological and molecular data.
Würl P; Lautenschläger C; Meye A; Schmidt H; Bache M; Rath FW; Schönfelder M; Taubert H
Anticancer Res; 2000; 20(3B):2065-72. PubMed ID: 10928153
[TBL] [Abstract][Full Text] [Related]
11. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
12. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
13. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
14. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
15. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance.
Suzuki M; Ohwada M; Saga Y; Kohno T; Takei Y; Sato I
Oncology; 2001; 60(2):170-5. PubMed ID: 11244333
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
17. [Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course].
Reles A; Press MF; Schönborn I; Lichtenegger W; Strohmeyer T
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():93-7. PubMed ID: 8672936
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
